Emma Maria Haapaniemi

This paper presents a non-viral HDR-based CRISPR/Cas9 protocol for editing primary T cells with up to 80% HDR efficiency, targeting small pathogenic variants in patient and healthy donor cells.

The paper identifies NFATC2-expressing cancer-associated fibroblasts in PDAC that improve treatment response and enhance ERBB-targeted therapies.

This paper edits the ADA2 p.R169Q mutation in human hematopoietic stem cells using CRISPR-Cas9 and HDR, showing improved efficiency with NHEJ inhibitors but increased chromosomal deletions.

This paper presents a T cell gene correction pipeline using CRISPR/Cas9 and HDR to correct monogenic mutations in IEI models, achieving up to 80% bi-allelic editing with no detectable off-target effects.

CHOPOFF improves CRISPR off-target detection by addressing limitations in symbolic alignments and introducing efficient data structures for accurate and fast prediction.

Cas9-induced double-strand breaks trigger p53/p21/RB1-dependent G1 arrest in RPE-1 cells; transient p53 inhibition via MDM2 markedly raises homologous recombination precision editing efficiency.